QOL, ADL and Pain Before and After Intervention With N3 From Krill With D3.

Survey of Chronic Pain Patients' Self-rated Quality of Life, ADL Function and Pain Before and After Intervention With Omega 3 Fatty Acids From Krill With Vitamin D3

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02008760

Enrollment

Registered

2013-12-11

Start date

2013-02-28

Completion date

2014-06-30

Last updated

2013-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Quality of Life

Keywords

pain, quality of life, ADL, DOLO test, compliance, D3

Brief summary

The aim of this project is investigation of patients' with chronic pain self-rated quality of life, ADL function and level of pain before and after 3 months of intervention with N-3 fatty acids from krill in combination with vitamin D3. Furthermore, the compliance of the patients and the effect of the intervention on the patients' vitamin D status and cardiovascular risk factors are studied.

Interventions

DIETARY_SUPPLEMENTOmega Krill with D3

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 18 year + * can read and understand danish

Exclusion criteria

* shellfish allergy * intake of anticoagulants and vitamin D * pacemaker * participating other studies

Design outcomes

Primary

Measure	Time frame
ADL function on a scale 0-11	february 2013-february 2014
pain on a scale 0-100 mm	february 2013-february 2014
Quality of life on a scale 0-100	february 2013-february 2014

Secondary

Measure	Time frame
compliance in %	february 2013-february 2014
changes at D3 levels	february 2013-february 2014

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026